Caliway Biopharmaceuticals (TWSE-6919) announced today that CBL-514's second Phase 2b clinical study (CBL-0205), sprung across 15 sites in the U.S. and Canada, successfully met its primary and all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback